This article reviews the research on the treatment of cigarette smoking in individuals who have comorbid mental illnesses or non-nicotinic addictions. The prevalence of smoking in mentally ill and substance-abusing populations is presented, as well as reasons for this high prevalence. The historical role of cigarettes and tobacco in mental illness and addiction is reviewed… Read More »»
Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings.
The National Institute of Mental Health (NIMH) convened a meeting in September 2005 to review tobacco use and dependence and smoking cessation among those with mental disorders, especially individuals with anxiety disorders, depression, or schizophrenia. Smoking rates are exceptionally high among these individuals and contribute to the high rates of medical morbidity and mortality in… Read More »»
The impact of the “Stirrup Some Fun” therapeutic horseback riding program: a qualitative investigation.
Therapeutic horseback riding is an intervention utilizing horses in the treatment of individuals with emotional, cognitive, and/or physical disabilities. The purpose of this study was to investigate the perceived impact of a therapeutic riding program on children with mild to moderate physical and mental disabilities. Two groups of participants including five children (with a variety… Read More »»
Use of smoking cessation therapies in individuals with psychiatric illness: an update for prescribers.
Individuals with mental illness are particularly disadvantaged by their use of tobacco, spending as much as 40% of their income on cigarettes. They also have increased mortality from cardiovascular and respiratory disorders. The most effective interventions to help psychiatric patients stop smoking are similar to those that are effective in the general population. These include… Read More »»
Survey of clinician attitudes toward smoking cessation for psychiatric and substance abusing clients.
The current study examined mental health clinician attitudes regarding smoking cessation for psychiatric and substance abusing patients. Participants included n = 15 never smokers, n = 12 former smokers, and n = 7 current smokers. There was a trend (p = 0.08) for current smokers as compared to former and never smokers to be less… Read More »»
A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia.
BACKGROUND: Individuals with schizophrenia smoke at higher rates (58%-88%) than the general population (approximately 22%), and have difficulty quitting. We determined whether the combination of sustained-release (SR) bupropion (BUP) with the transdermal nicotine patch (TNP) was well-tolerated and superior to placebo (PLO)+TNP for smoking cessation in schizophrenia. METHODS: A 10-week, double-blind, placebo-controlled trial of BUP… Read More »»
Smoking is the leading cause of preventable death in the United States. This public health problem is of particular concern among individuals with substance use disorders in that they smoke at a greater rate than the general public. Smoking-related illness represents a major source of preventable death in persons with drug dependencies. Substance abuse treatment… Read More »»